Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI

<b>Objective</b> Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations have higher response rate and more prolonged survival following treatment with single-agent EGFR tyrosine kinase inhibitor (EGFR-TKI) compared with patients with...

Full description

Bibliographic Details
Main Authors: Guo-Hao Xia, Yun Zeng, Ying Fang, Shao-Rong Yu, Li Wang, Mei-Qi Shi, Wei-Li Sun, Xin-En Huang, Jia Chen, Ji-Feng Feng
Format: Article
Language:English
Published: China Anti-Cancer Association 2014-12-01
Series:Cancer Biology & Medicine
Subjects:
Non-small cell lung cancer (NSCLC)
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
erlotinib
gefitinib
chemotherapy
acquired resistance
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/825

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/825

Similar Items